Differential possibilities of determination of molecular markers in uterine aspirate in endometrial and non-endometrial cancer of uterine body
https://doi.org/10.33667/2078-5631-2023-10-25-28
Abstract
Objective. To evaluate the diagnostic informativeness of determining the concentration of the MCM5 proliferation marker in the uterine aspirate for the detection of uterine body cancer (UBC) and the differential identifiation of the risk group for patients with suspected non-endometrioid endometrial cancer.
Materials and methods. 104 patients diagnosed with UBC and 32 healthy patients of the control group were examined. According to the histological type, 79 (76 %) patients had endometrial cancer, 16 (15 %) had serous and 9 (9 %) clear cell cancer. Endometrial aspiration biopsy was obtained by Pipel biopsy using a two-channel Pipelle catheter. Direct quantitative determination of the concentration of MCM5 in the uterine aspirate cell homogenate was carried out by enzyme-linked immunosorbent assay using specifi MCM5 ELISA test systems.
Results. It was found that when the concentration of MCM5 in the uterine aspirate exceeds 11.38 pg/ml, the detection of early-stage UBC is possible with a diagnostic sensitivity of 96.12 % and a specifiity of 78.79 %. When the concentration of MCM5 in the uterine aspirate exceeds 56.9 pg/ml, the relative risk of detecting rare forms of UBC increases (p < 0.0001) by 59.7 times.
Conclusions. Determination of the concentration of the protein of the minichromosomal protection family MCM5 in the aspirate of the uterine cavity is informative for the early detection of UBC.
About the Authors
N. V. Kovalenko
Volgograd Regional Clinical Oncological Dispensary
Russian Federation
Russian Federation
Kovalenko Nadezhda V., PhD Med, chief physician, head of Dept of Oncology, Hematology and Transplantology
Volgograd
A. Yu. Maksimov
National Medical Research Centre of Oncology
Russian Federation
Russian Federation
Maksimov Alexey Yu., DM Sci (habil.), professor, deputy CEO
Rostov-on-Don
E. V. Verenikina
National Medical Research Centre of Oncology
Russian Federation
Russian Federation
Verenikina Ekaterina V., DM Sci (habil.), head of Dept of oncogynecology
Rostov-on-Don
A. A. Demidova
Rostov State Medical University
Russian Federation
Russian Federation
Demidova Alexandra A., DM Sci (habil.), associate professor, head of Dept of Medical and Biological Physics
Rostov-on-Don
References
1. Siegel R. L., Miller K. D., Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020 Jan; 70 (1): 7–30. https://doi.org/10.3322/caac.21590
2. Simon M. S., Hastert T. A., Barac A., Banack H. R., Caan B. J., Chlebowski R. T. et al. Cardiometabolic risk factors and survival after cancer in the Women’s Health Initiative. Cancer. 2021 Feb 15; 127 (4): 598–608 https://doi.org/10.1002/cncr.33295.
3. Lu K. H., Broaddus R. R. Endometrial Cancer. N Engl J Med. 2020 Nov 19; 383 (21):2053–2064. https://doi.org/10.1056/nejmra1514010.
4. Bogani G., Ray-Coquard I., Concin N., Ngoi N., Morice P., Enomoto T. Uterine Serous Carcinoma. Gynecol Oncol. 2021 July; 162 (1): 226–234. https://doi.org/10.1016/j.ygyno.2021.04.029.
5. Wang Y., Yu M., Yang J. X., Cao D. Y., Shen K., Lang J. H. Clinicopathological and survival analysis of uterine papillary serous carcinoma: a single institutional review of 106 cases. Cancer Manag Res. 2018 Oct 25; 10: 4915–4928. https://doi.org/10.2147/cmar.s179566.
6. Soslow R.A, Tornos C., Park K. J., Malpica A., Matias-Guiu X., Oliva E. et al. Endometrial Carcinoma Diagnosis: Use of FIGO Grading and Genomic Subcategories in Clinical Practice: Recommendations of the International Society of Gynecological Pathologists. Int J Gynecol Pathol. 2019 Jan; 38 Suppl 1: S 64–S 74. https://doi.org/10.1097/pgp.0000000000000518
7. Карпова А. Е., Шабалова И. П., Созаева Л. Г., Тумгоева Л. Б. Значение комплексного цитологического исследования в диагностике патологии эндометрия (обзор литературы). Клиническая лабораторная диагностика. 2021; 66 (2): 87–94. https://doi.org/10.51620/0869–2084–2021–66–2–87–94 Karpova A. E., Shabalova I. P., Sozaeva L. G., Tumgoeva L. B. Comprehensive approach to diagnostic cytology in endometrial pathology (review of literature). Russian Clinical Laboratory Diagnostics. 2021; 66 (2): 87–94 (in Russ.). DOI: http://dx.doi.org/10.51620/0869–2084–2021–66–2–87–94
8. Ura B., Monasta L., Arrigoni G., Franchin C., Radillo O., Peterlunger I., Ricci G., Scrimin F. A proteomic approach for the identifiation of biomarkers in endometrial cancer uterine aspirate. Oncotarget. 2017; 8: 109536–109545. https://doi.org/10.18632/oncotarget.22725
9. Li S., Jiang Z., Li Y., Xu Y. Prognostic signifiance of minichromosome maintenance MRNA expression in human lung adenocarcinoma. Oncology Reports. 2019; 42 (6): 2279–2292. https://doi.org/10.3892/or.2019.7330
10. Everson M., Magee C., Alzoubaidi D., Brogden S., Graham D., Lovat L. B. et al. Minichromosomal maintenance component complex 5 (MCM5) as a marker of Barrett’s esophagus-related neoplasia: A feasibility study. Dig Dis Sci. 2019; 64: 2815–2822. https://doi.org/10.1007/s10620–019–05607–5
11. Liao X., Han C., Wang X., Huang K., Yu T., Yang C. et al. Prognostic value of minichromosome maintenance MRNA expression in early-stage pancreatic ductal adenocarcinoma patients after pancreaticoduodenectomy. Cancer Management and Research. 2018; 10: 3255–3271. https://doi.org/10.2147/cmar.s171293
12. Wang D., Li Q., Wang H. The role of MCM5 expression in cervical cancer: Correlation with progression and prognosis. Biomed Pharmacother. 2018 Feb; 98: 165–172. https://doi.org/10.1016/j.biopha.2017.12.006.
13. Deng L., Wu R. A., Sonneville R., Kochenova O. V., Labib K., Pellman D., Walter J. C. Mitotic CDK promotes replisome disassembly, fork breakage, and complex DNA rearrangements. Molecular Cell. 2019; 73 (5): 915–929. https://doi.org/10.1016/j.molcel.2018.12.021
14. Dudderidge T., Stockley J., Nabi G., Mom J., Umez-Eronini N., Hrouda D. et al. A Novel, non-invasive Test Enabling Bladder Cancer Detection in Urine Sediment of Patients Presenting with Haematuria – A Prospective Multicentre Performance Evaluation of ADXBLADDER. European Urology Oncology. 2020; 3: 42–46. https://doi.org/10.1016/j.euo.2019.06.006
Review
For citations:
Kovalenko N.V., Maksimov A.Yu., Verenikina E.V., Demidova A.A. Differential possibilities of determination of molecular markers in uterine aspirate in endometrial and non-endometrial cancer of uterine body. Medical alphabet. 2023;(10):25-28. (In Russ.) https://doi.org/10.33667/2078-5631-2023-10-25-28
Views:
284
Email this article 